Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659776 · ClinicalTrials.gov registry record · Phase 2
MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
A Phase 2 study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT00659776: Clinical Trial Phase 2 study, sponsored by Oregon Health and Science University.
NCT00659776 is a Phase 2 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 255 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00659776, a Phase 2 study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
This exploratory study utilizes ferumoxytol, an iron oxide nanoparticle MR contrast agent for imaging various inflammatory processes in the head and neck region, spine, including the central nervous system. The protocol enrolls subjects with radiological or histological diagnosis of unknown, dural, or parenchymal CNS lesions, multiple sclerosis, TIA or stroke, vasculitis, or other vascular lesions; arterial vasculopathy and venous thrombosis; or enlarged cervical lymph nodes. The main purpose of this study is to better understand the underlying cellular mechanisms, contrast agent extravasation, uptake into macrophages and to assess its value in clinical MR imaging.
Interventions
- DRUG Ferumoxytol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2004-07 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
Why NCT00659776 stopped before completion
NCT00659776 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher).
The record links to 0 conditions, and to 1 intervention - of which Ferumoxytol is the first listed.
NCT00659776 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00659776 about?
NCT00659776 is a clinical study titled "MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation". This exploratory study utilizes ferumoxytol, an iron oxide nanoparticle MR contrast agent for imaging various inflammatory processes in the head and neck region, spine, including the central nervous system. The protocol enrolls subjects with radiological or histological diagnosis of unknown, dural, ...
What is the current status of trial NCT00659776?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2004-07. Estimated completion is 2021-12.
What interventions are being tested in trial NCT00659776?
The interventions under investigation include: Ferumoxytol (DRUG).
Who is sponsoring clinical trial NCT00659776?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00659776's enrollment target sits among peer trials
255 218th of 2000 higher than 1,782 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia